TG Therapeutics Results Published in NEJM
TG Therapeutics (TGTX) results from the ULTIMATE I & II Phase 3 trials evaluating the firm’s investigational monoclonal antibody product ublituximab in patients with relapsing forms of multiple sclerosis (RMS) were This content is for paid subscribers.
TG Therapeutics: Promising Investigational Monoclonal Antibody Ublituximab for Relapsing Form of M.S.
Impacting News August 31, 2022
Impacting News
August 31, 2022
